NuCana's R&D On Agents For Drug-Resistant Cancers Gets IPO Boost
Executive Summary
The UK biotech plans to move its early clinical-stage anticancers, designed to improve the efficacy and tolerability of established agents, through its R&D pipeline with the proceeds of its recent US IPO.